Ipsen
1 known investors
Ipsen is a biopharmaceutical company that develops and commercializes medicines across three therapeutic areas—oncology, rare diseases, and neuroscience—for patients with high unmet medical needs. Its portfolio includes treatments for neuroendocrine tumors and cancers of the kidney, liver, pancreas, thyroid, prostate and breast, as well as rare bone, liver, and neurogenetic disorders and neurological conditions.
BiotechHealthtech
Investors · 1
Acquisitions · 2
Early investors' stakes continue via these dealsImCheck Therapeutics
Developer of antibody therapeutics targeting butyrophilin checkpoint molecules for cancer; acquired by Ipsen in 2025.
Memo Therapeutics
European biotech developing first-in-class antibody potravitug; agreed to be acquired by Ipsen for over €700 million.
In the news
Frequently asked questions
- What does Ipsen do?
- Ipsen is a biopharmaceutical company that develops and commercializes medicines across three therapeutic areas—oncology, rare diseases, and neuroscience—for patients with high unmet medical needs. Its portfolio includes treatments for neuroendocrine tumors and cancers of the kidney, liver, pancreas, thyroid, prostate and breast, as well as rare bone, liver, and neurogenetic disorders and neurological conditions.
- Who are Ipsen's investors?
- Ipsen's investors include Ysios Capital.